EyePoint Pharmaceuticals commercially launched its biopharmaceutical product Yutiq in the U.S.
Three insights:
1. Yutiq is an FDA-approved, three-year micro-insert for the treatment of chronic, non-infectious posterior segment uveitis.
2. Yutiq utilizes EyePoint's Durasert drug delivery technology. It contains 0.18 milligrams of fluocinolone acetonide, designed to release consistently for up to 36 months.
3. In conjunction, the company launched EyePoint Assist, a program to ensure eligible patients in need of financial assistance have access to Yutiq.